Evidence map›Paper›PMID 40757658›Full record

GuidelineClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness.

Adarsh Bhimraj, Yngve Falck-Ytter, Lindsey R Baden, Roger Bedimo, Kelly Cawcutt, Vincent Chi-Chung Cheng, Kara W Chew, Kathleen Chiotos, Eric S Daar, Amy L Dzierba and 19 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. CROI 2026: Acute and Postacute COVID-19.Topics in antiviral medicine · 2026
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Adarsh BhimrajDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0009-0005-5008-3128
Yngve Falck-YtterDepartment of Medicine, Case Western Reserve University, School of Medicine, Cleveland, Ohio, USA.
Lindsey R BadenHarvard Medical School, Boston, Massachusetts, USA.
Roger BedimoDepartment of Medicine, UT Southwestern/VA North Texas Health Care System, Dallas, Texas, USA.ORCID 0000-0001-9794-0389
Kelly CawcuttDivision of Infectious Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Vincent Chi-Chung ChengDepartment of Microbiology, Queen Mary Hospital, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
Kara W ChewDepartment of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA.ORCID 0000-0003-4865-4348
Kathleen ChiotosDepartment of Anesthesiology and Critical Care, Children's Hospital of Philadelphia/University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-0204-8708
Eric S DaarDepartment of Medicine, Harbor-UCLA Medical Center, Torrance, California, USA.ORCID 0000-0003-1880-7331
Amy L DzierbaDepartment of Medicine, New York University Grossman School of Medicine, New York City, New York, USA.
David V GliddenDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Erica J HardyDepartments of Medicine and Obstetrics and Gynecology, Brown University, Providence, Rhode Island, USA.
Steven JohnsonDepartment of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
Arthur Y KimHarvard Medical School, Boston, Massachusetts, USA.
Jonathan Z LiHarvard Medical School, Boston, Massachusetts, USA.
Christine MacBrayneDepartment of Pharmacy, Children's Hospital Colorado, Aurora, Colorado, USA.
Greg S MartinDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-9684-7593
Nandita NadigDivision of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Mari M NakamuraAntimicrobial Stewardship Program and Division of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts, USA.
Jeffrey C PearsonDepartment of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Laura RileyNew York-Presbyterian Hospital/Weill Cornell Medical Center, New York City, New York, USA.ORCID 0000-0001-5043-4569
Robert W ShaferDepartment of Medicine, Stanford University, Palo Alto, California, USA.
Shmuel ShohamDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-7276-7786
Amy Hirsch ShumakerDepartment of Medicine, Case Western Reserve University, School of Medicine, Cleveland, Ohio, USA.
Pablo TebasDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0001-5345-7942
Phyllis C TienDepartment of Medicine, UCSF/VA San Francisco Health Care System, San Francisco, California, USA.
Jennifer LovelessClinical Affairs and Practice Guidelines, Infectious Diseases Society of America, Arlington, Virginia, USA.
Rebecca L MorganDepartment of Medicine, Case Western Reserve University, School of Medicine, Cleveland, Ohio, USA.
Rajesh T GandhiHarvard Medical School, Boston, Massachusetts, USA.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
HHSInfectious Diseases Society of AmericaNCI NIH HHSNIH HHS 75N91019D00024U.S. Government
6 · The paper itself

Abstract

As the first part of several focused updates to the clinical practice guideline on the treatment and management of COVID-19 in adults, children, and pregnant people, developed by the Infectious Diseases Society of America, the panel presents four new recommendations. These recommendations include pre-exposure prophylaxis for immunocompromised persons and treatment of severe or critical COVID-19. The panel's recommendations are based upon evidence derived from systematic literature reviews and adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach.

Indexed as

COVID-19COVID-19 Drug TreatmentInfliximabPre-Exposure ProphylaxisAdultCritical IllnessFemaleHumansImmunocompromised HostPregnancySARS-CoV-2Societies, MedicalInfliximababataceptCOVID-19infliximabpemivibartvilobelimab

Identifiers

PMID40757658
PMCPMC12809781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.